CO5271658A1 - Antagonistas del factor liberador de corticotropina - Google Patents

Antagonistas del factor liberador de corticotropina

Info

Publication number
CO5271658A1
CO5271658A1 CO01003117A CO01003117A CO5271658A1 CO 5271658 A1 CO5271658 A1 CO 5271658A1 CO 01003117 A CO01003117 A CO 01003117A CO 01003117 A CO01003117 A CO 01003117A CO 5271658 A1 CO5271658 A1 CO 5271658A1
Authority
CO
Colombia
Prior art keywords
alkyl
cycloalkyl
alkylene
cycloalkylene
heterocycloalkyl
Prior art date
Application number
CO01003117A
Other languages
English (en)
Inventor
Liang Chen Yuhpyng
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5271658A1 publication Critical patent/CO5271658A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Un compuesto de la fórmula <EMI FILE="01003117_1" ID="1" IMF=JPEG >o una de sus sales farmacéuticamente aceptables, donde las líneas de puntos representan dobles enlaces opcionales, con la condición de que cuando la línea de puntos en C --- G representa un doble enlace entonces la línea de puntos en N(R6) --- C no representa un doble enlace; y con la condición de que cuando la línea de puntos en N(R6) --- C representa un doble enlace, R6 está ausente de la fórmula III y la línea de puntos en C --- G no representa un doble enlace; A es -CR7 o N; B es -NR1R2, CR1R2R11, -C(=CR2R12)R1, -NHCHR1R2. -OCHR1R2, -SCHR1R2, -CHR2OR1, -CHR1OR2, -CHR2SR1, -C(S)R2, -C(O)R2, -CHR2NR1R2, -CHR1NHR2, -CHR1N(CH3)R2, o -NR12NR1R2; cuando la línea de puntos en C --- G representa un doble enlace, entonces G es hidrógeno, oxígeno, azufre, NH o N(alquilo C1-C4); cuando la línea de puntos en C --- G no representa un doble enlace, entonces es -C(H)(NH2), CH2, -C(H)(metoxi), -C(H)(etoxi), -C(H)(O(alquilo C3-C4)), -C(H)(halo), -C(H)(trifluorometoxi), -C(H)(metilo), -C(H)(etilo), -C(H)(alquilo C3-C4), -C(H)(S(alquilo C1-C4)), C(alquilo C1-C4)(alquilo C1-C4), ciclopropilo, -C(H)(ciclopropilo), tiometoxi, -C(H)(NH2), -C(H)(NHCH3), -C(H)(N(CH3)2) o -C(H)(trifluorometilo); donde dichos grupos ciclopropilo, metoxi, etoxi, alquilo C3-C4 y alquilo C1-C4 de C --- G pueden estar opcionalmente sustituidos con un OH, metoxi, o trifluorometoxi, o pueden estar opcionalmente sustituidos con uno a seis átomos de flúor; Y es CH o N; Z es NH, O, S, -N(alquilo C1-C2), -NC(O)CF3, o -C(R13R14), donde R13 y R14 son cada uno, independientemente, hidrógeno, trifluorometilo o metilo, o uno de R13 y R14 es ciano y el otro es hidrógeno o metilo, o -C(R13R14) es un - 2 -grupo ciclopropilo, o Z es nitrógeno o CH y forma un anillo heterocíclico de cinco o seis miembros condensado con R5, cuyo anillo comprende opcionalmente dos o tres miembros heterólogos adicionales seleccionados independientemente entre oxígeno, nitrógeno, NR12, y S(O)m, y opcionalmente comprende de uno a tres dobles enlaces, y está opcionalmente sustituido con halo, alquilo C1-C4, -O(alquilo C1-C4), NH2, NHCH3, N(CH3)2, CF3, o OCF3, con la condición de que dicho anillo no contiene ninguno de los enlaces -S-S-, -S-O-, -N-S-, o OO, y no comprende más de dos miembros heterológos oxígeno o S(O)m; R1 es C(O)H, C(O)(alquilo C1-C6), C(O)(alquileno C1-C6)(cicloalquilo C3-C8), C(O)(ciclo alquileno C3-C8)(cicloalquilo C3-C8), C(O)(alquileno C1-C6)(heterocicloalquilo C4-C8), -C(O)(cicloalquileno C3-C8)(heterocicloalquilo C4-C8), -alquilo C1-C6, cicloalquilo C3-C8, heterocicloalquilo C4-C8, -(alquileno C1-C6)(cicloalquilo C3-C8), -(cicloalquileno C3-C8)(cicloalquilo C3-C8), -(alquileno C1-C6)(heterocicloalquilo C4-C8), -(cicloalquileno C3-C8)(heterocicloalquilo C4-C8), o -O-arilo, o -O-(alquileno C1-C6)-arilo; donde dichos grupos arilo, heterocicloalquilo C4-C8, alquilo C1-C6, cicloalquilo C3-C8, cicloalquileno C3-C8, y alquileno C1-C6 pueden estar cada uno, independientemente, opcionalmente sustituidos con uno a seis flúor y pueden estar cada uno, independientemente. opcionalmente sustituidos con uno o dos sustituyentes R8 independientemente seleccionados del grupo constituido por alquilo C1-C4, -cicloalquilo C3-C8, hidroxi, cloro, bromo, yodo, CF3, -O-(alquilo C1-C6), -O-(cicloalquilo C3-C5), -O-CO-(alquilo C1-C4), -O-CO-NH(alquilo C1-C4), -O-CO-N(R24)(R25), -N(R24)(R25), -S(alquilo C1-C4), -S(cicloalquilo C3-C5), N(alquilo C1-C4)CO(alquilo C1-C4), -NHCO(alquilo C1-C4), -COO(alquilo C1-C4), CONH-(alquilo C1-C4), -CON(alquilo C1-C4)(alquilo C1-C2), CN, NO2, -OSO2(alquilo C1-C4), S (alquilo C1-C6)(alquilo C1-C2)l-, -SO(alquilo C1-C4) y -SO2(alquilo C1-C4); y donde los restos alquilo C1-C6, alquileno C1-C6, cicloalquilo C5-C8, cicloalquileno C5-C8, y heterocicloalquilo C5-C8 de R1 pueden contener independientemente opcionalmente de uno a tres dobles o triples enlaces; y donde los restos alquilo C1-C4 y los restos alquilo C1-C6 de R8 pueden estar independientemente opcionalmente sustituidos con hidroxi, amino, alquilo C1-C4, arilo, -CH2-arilo, cicloalquilo C3-C5, o -O-(alquilo C1-C4), y pueden estar independientemente opcionalmente sustituidos con uno a seis flúor, y pueden contener opcionalmente uno o dos dobles o triples enlaces; y donde cada uno de los grupos heterocicloalquilo de R1 contiene de uno a tres restos heterólogos seleccionados entre oxígeno, S(O)m, nitrógeno, y NR12; R2 es hidrógeno, alquilo C1-C12, cicloalquilo C3-C8, heterocicloalquilo C4-C8, -(alquileno C1-C6)(cicloalquilo C3-C8), -(cicloalquileno C3-C8)(cicloalquilo C3-C8), -(alquileno C1-C6)(heterocicloalquilo C4-C8), -(cicloalquileno C3-C8)(heterocicloalquilo C4-C8), arilo, -(alquileno C1-C6)arilo, o -(cicloalquileno C3-C8)(arilo); donde cada uno de los grupos R2 anteriores puede estar opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre cloro, flúor, y alquilo C1-C6, donde uno de dichos uno a tres sustituyentes puede ser seleccionado adicionalmente entre bromo, yodo, alcoxi C1-C6, -OH, -O-CO-(alquilo C1-C6), -O-CO-N(alquilo C1-C4)(alquilo C1-C2), -S(alquilo C1-C6), -S(O)(alquilo C1-C6), -S(O)2(alquilo C1-C6), S (alquilo C1-C6)(alquilo C1-C2)l-, CN, y NO2; y donde los restos alquilo C1-C12, -(alquileno C1-C6), -(cicloalquilo C5-C8), -(cicloalquileno C5-C8), y -(heterocicloalquilo C5-C8) de R2 pueden contener independientemente opcionalmente de uno a tres dobles o triples enlaces; y donde cada uno de los grupos heterocicloalquilo de R2 contiene de uno a tres restos heterólogos seleccionados entre oxígeno, S(O)m, nitrógeno, y NR12; o cuando R1 y R2 están como en -NHCHR1R2, -OCHR1R2, -SCHR1R2, -CHR1R2 o -NR1R2, R1 y R2 de B pueden formar un anillo saturado de 5 a 8 miembros que puede contener opcionalmente uno o dos dobles enlaces y en el cual uno o dos de los carbonos del anillo puede estar opcionalmente reemplazado por un oxígeno, S(O)m, nitrógeno o NR12; y cuyo anillo carbocíclico puede estar opcionalmente sustituido con 1 a 3 sustituyentes seleccionados del grupo constituido por hidroxi, alquilo C1-C4, flúor, cloro, bromo, yodo, CF3, -O-(alquilo C1-C4), -O-CO-(alquilo C1-C4), -O-CO-NH(alquilo C1-C4), -O-CO-N(alquilo C1-C4)(alquilo C1-C2), -NH(alquilo C1-C4), -N(alquilo C1-C2)(alquilo C1-C4), -S(alquilo C1-C4), -N(alquilo C1-C4)CO(alquilo C1-C4), -NHCO(alquilo C1-C4), -COO(alquilo C1-C4), -CONH(alquilo C1-C4), -CON(alquilo C1-C4)(alquilo C1-C2), CN, NO2, -OSO2(alquilo C1-C4), -SO(alquilo C1-C4) y -SO2(alquilo C1-C4) donde uno de dichos uno a tres sustituyentes puede ser adicionalmente seleccionado de fenilo; R3 es metilo, etilo, flúor, cloro, bromo, yodo, ciano, metoxi, OCF3, NH2, NH(alquilo C1-C2), N(CH3)2, -NHCOCF3, -NHCH2CF3, S(O)m(alquilo C1-C4), CONH2, -CONHCH3, CON(CH3)2, -CF3, o CH2OCH3;R4 es hidrógeno, alquilo C1-C4, cicloalquilo C3-C5, -(alquileno C1-C4)(cicloalquilo C3-C5), -(cicloalquileno C3-C5)(cicloalquilo C3-C5), ciano, flúor, cloro, bromo, yodo, -OR24, alcoxi C1-C6, -O-(cicloalquilo C3-C5), -O-(alquileno C1-C4)(cicloalquilo C3-C5), - 3 --O-(cicloalquileno C3-C5)(cicloalquilo C3-C5), -CH2SC(S)O(alquilo C1-C4), -CH2OCF3, -CF3, amino, nitro, -NR24R25, -(alquileno C1-C4)-OR24, -(alquileno C1-C4)Cl, -(alquileno C1-C4)NR24R25-NHCOR24, -NHCONR24R25, -C=NOR24, -NHNR24R25, -S(O)mR24, C(O)R24, -OC(O)R24, -C(O)CN, C(O)NR24R25, -C(O)NHNR24R25, y -COOR24, donde los grupos alquilo y alquileno de R4 pueden contener independientemente opcionalmente uno o dos dobles o triples enlaces y pueden estar independientemente opcionalmente sustituidos con uno o dos sustituyentes R10 independientemente seleccionados entre hidroxi, amino, -NHCOCH3, -NHCOCH2Cl, -NH(alquilo C1-C2), -N(alquilo C1-C2)(alquilo C1-C2), -COO(alquilo C1-C4), -COOH, -CO(alquilo C1-C4), alcoxi C1-C6, tioalquilo C1-C3, ciano y nitro, y con uno a cuatro sustituyentes seleccionados independientemente entre flúor y cloro; R5 es arilo o heteroarilo y está sustituido con uno a cuatro sustituyentes R27 indepen dientemente seleccionados entre halo, alquilo C1-C10, -(alquileno C1-C4)(cicloalquilo C3-C8), -(alquileno C1-C4)(heterocicloalquilo C4-C8), -(cicloalquilo C3-C8), -(heterocicloalquilo C4-C8), -(cicloalquileno C3-C8), -(cicloalquilo C3-C8), -(cicloalquileno C3-C8) (heterocicloalquilo C4-C8), haloalquilo C1-C4, haloalcoxi C1-C4, nitro, ciano, -NR24R25, -NR24COR25, -NR24CO2R26, -COR24, -OR25, -CONR24R25, -CO(NOR22)R23, -CO2R26, -C=N(OR22)R23, y -S(O)mR23; donde dichos grupos alquilo C1-C10, cicloalquilo C3-C8, (alquileno C1-C4), (cicloalquilo C3-C8), (cicloalquileno C3-C8), y (heterocicloalquilo C4-C8) pueden estar opcionalmente sustituidos con uno a tres sustituyentes independientemente seleccionados entre alquilo C1-C4, cicloalquilo C3-C8, (alquileno C1-C4) (cicloalquilo C3-C8), -(cicloalquileno C3-C8)(cicloalquillo C3-C8), haloalquilo C1-C4, hidroxi, alcoxi C1-C6, nitro, halo, ciano, -NR24R25, -NR24COR25, NR24CO2R26, -COR24, -OR25, -CONR24R25, CO2R26, -CON(OR22)R25, y -S(O)mR23; y donde dos sustituyentes adyacentes del grupo R5 pueden formar opcionalmente un anillo de 5-7 miembros, saturado o insaturado, condensado con R5, cuyo anillo puede contener opcionalmente uno, dos, o tres miembros heterólogos independientemente seleccionados entre O,S(O)m, y N, pero ninguno de los enlaces -S-S-, -O-O-, -S-O-, o -N-S-, y cuyo anillo está opcionalmente sustituido con alquilo C1-C4, cicloalquilo C3-C8, -(alquileno C1-C4) (cicloalquilo C3-C8), -(cicloalquileno C3-C8)(cicloalquilo C3-C8), haloalquilo C1-C4, nitro, halo, ciano, -NR24R25, NR24COR25, NR24CO2R26, -COR24, -OR25, -CONR24R25, CO2R26, -CON(OR26)R25, o -S(O)mR23; donde uno de dichos uno a cuatro sustituyentes opcionales R27 puede ser adicionalmente seleccionado entre -SO2NH(alquilo C1-C4), -SO2NH(alquileno C1-C4)(cicloalquilo C3-C8), -SO2NH(cicloalquilo C3-C8), -SO2NH(cicloalquileno C3-C8)(cicloalquilo C3-C8), -SO2N(alquilo C1-C4)(alquilo C1-C2), -SO2NH2, -NHSO2(alquilo C1-C4), -NHSO
CO01003117A 2000-01-18 2001-01-17 Antagonistas del factor liberador de corticotropina CO5271658A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17661100P 2000-01-18 2000-01-18

Publications (1)

Publication Number Publication Date
CO5271658A1 true CO5271658A1 (es) 2003-04-30

Family

ID=22645084

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01003117A CO5271658A1 (es) 2000-01-18 2001-01-17 Antagonistas del factor liberador de corticotropina

Country Status (36)

Country Link
US (1) US6833378B2 (es)
EP (1) EP1263732A1 (es)
JP (1) JP2003520272A (es)
KR (1) KR20020063934A (es)
CN (1) CN1395566A (es)
AP (1) AP2002002583A0 (es)
AR (1) AR027221A1 (es)
AU (1) AU779995B2 (es)
BG (1) BG106853A (es)
BR (1) BR0107662A (es)
CA (1) CA2397633A1 (es)
CO (1) CO5271658A1 (es)
CR (1) CR6698A (es)
CZ (1) CZ20022390A3 (es)
EA (2) EA200300834A1 (es)
EE (1) EE200200400A (es)
GT (1) GT200100007A (es)
HN (1) HN2001000006A (es)
HR (1) HRP20020599A2 (es)
HU (1) HUP0204272A3 (es)
IL (1) IL150632A0 (es)
IS (1) IS6445A (es)
MA (1) MA26864A1 (es)
MX (1) MXPA02007047A (es)
NO (1) NO20023424L (es)
OA (1) OA12157A (es)
PA (1) PA8510001A1 (es)
PE (1) PE20011166A1 (es)
PL (1) PL357589A1 (es)
SK (1) SK10062002A3 (es)
SV (1) SV2002000289A (es)
TN (1) TNSN01008A1 (es)
UY (1) UY26544A1 (es)
WO (1) WO2001053263A1 (es)
YU (1) YU54402A (es)
ZA (1) ZA200205660B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956047B1 (en) * 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
EP1449532A1 (en) * 1999-08-27 2004-08-25 Pfizer Products Inc. Compound [2-(4-chloro-2,6-dimethyl-phenoxy)- 3,6-dimethyl-pyridin-4-yl]- (1-ethyl-propyl)- amine and use as CRF antagonist
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
EP1688408A3 (en) * 2002-08-08 2007-08-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
NZ537952A (en) 2002-08-08 2008-04-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
WO2004062665A1 (en) * 2003-01-16 2004-07-29 Sb Pharmco Puerto Rico Inc Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7112585B2 (en) 2003-04-18 2006-09-26 Bristol-Myers Squibb Company Pyrimidine derivatives as corticotropin releasing factor inhibitors
US7030145B2 (en) 2003-04-18 2006-04-18 Bristol-Myers Squibb Company Pyridinyl derivatives for the treatment of depression
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP2287166A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP1701961A1 (en) * 2004-01-06 2006-09-20 Taisho Pharmaceutical Co., Ltd Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP4185154B2 (ja) 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害治療用の置換モルホリン化合物
WO2005113511A1 (en) 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
EP1827438B2 (en) 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US8153791B2 (en) 2005-12-21 2012-04-10 Janssen Pharmaceutica N.V. Substituted pyrimidinyl oxime kinase inhibitors
WO2007109783A2 (en) * 2006-03-23 2007-09-27 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
PT2076508E (pt) 2006-10-18 2011-03-07 Pfizer Prod Inc Compostos de ureia de éter biarílico
WO2009144632A1 (en) * 2008-05-30 2009-12-03 Pfizer Limited Novel compounds
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
HRP20230546T1 (hr) 2013-06-27 2023-08-04 Pfizer Inc. Heteroaromatski spojevi i njihova upotreba kao dopaminskih d1 liganada
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
EA034891B1 (ru) 2015-03-06 2020-04-02 Фармакеа, Инк. Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
ES2872553T3 (es) 2015-03-06 2021-11-02 Pharmakea Inc Inhibidores de lisil oxidasa tipo-2 y usos de los mismos
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018007331A1 (en) * 2016-07-08 2018-01-11 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
AU2017324445A1 (en) 2016-09-07 2019-04-11 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
CN109906222B (zh) * 2016-09-07 2023-08-01 加利福尼亚大学董事会 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
KR102615565B1 (ko) 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
EP3582772A1 (en) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
MY195013A (en) 2017-03-13 2022-12-31 Raqualia Pharma Inc Tetrahydroquinoline derivatives as p2x7 receptor antagonists
WO2020168068A1 (en) * 2019-02-13 2020-08-20 The University Of Vermont And State Agricultural College Small molecule antagonist to pacap receptor and uses thereof
US20220402881A1 (en) * 2019-11-06 2022-12-22 Albert Einstein College Of Medicine Small molecule prostagladin transport inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145287A1 (de) 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
EP0264883A3 (en) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
CA2051012C (en) 1990-09-14 2002-04-02 David R. Borcherding Carbocyclic adenosine analogs useful as immunosupressants
DE59303950D1 (de) 1992-08-10 1996-10-31 Volkswagen Ag Schalteinrichtung für ein Getriebe
JP2895961B2 (ja) * 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
CN1142817A (zh) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
US6130188A (en) * 1998-05-05 2000-10-10 American Cyanamid Company Herbicidal pyridine compounds
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors

Also Published As

Publication number Publication date
EP1263732A1 (en) 2002-12-11
MXPA02007047A (es) 2002-12-13
EA200200688A1 (ru) 2003-02-27
AU2390501A (en) 2001-07-31
CN1395566A (zh) 2003-02-05
EE200200400A (et) 2003-10-15
SV2002000289A (es) 2002-07-16
AR027221A1 (es) 2003-03-19
NO20023424L (no) 2002-09-10
NO20023424D0 (no) 2002-07-17
MA26864A1 (fr) 2004-12-20
US6833378B2 (en) 2004-12-21
IS6445A (is) 2002-06-25
CZ20022390A3 (cs) 2003-08-13
HUP0204272A2 (hu) 2003-03-28
BR0107662A (pt) 2002-11-19
HN2001000006A (es) 2001-06-13
CA2397633A1 (en) 2001-07-26
PE20011166A1 (es) 2001-11-13
IL150632A0 (en) 2003-02-12
OA12157A (en) 2006-05-08
PL357589A1 (en) 2004-07-26
AP2002002583A0 (en) 2002-09-30
GT200100007A (es) 2001-10-19
AU779995B2 (en) 2005-02-24
SK10062002A3 (sk) 2004-05-04
WO2001053263A1 (en) 2001-07-26
KR20020063934A (ko) 2002-08-07
TNSN01008A1 (fr) 2005-11-10
PA8510001A1 (es) 2002-12-11
BG106853A (bg) 2003-01-31
HRP20020599A2 (en) 2004-08-31
US20020016328A1 (en) 2002-02-07
CR6698A (es) 2004-01-14
ZA200205660B (en) 2003-10-09
YU54402A (sh) 2005-11-28
HUP0204272A3 (en) 2005-03-29
UY26544A1 (es) 2001-08-27
EA200300834A1 (ru) 2004-02-26
JP2003520272A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
CO5271658A1 (es) Antagonistas del factor liberador de corticotropina
CO5070570A1 (es) DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR041260A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
AR067443A1 (es) Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central
AR033306A1 (es) Compuestos
ES2330313T3 (es) Derivados de tiofeno como agentes antivirales contra infeccion por flavivirus.
CO5690588A2 (es) Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor
AR040080A1 (es) Inhibidores del virus de la hepatitis c
AR036674A1 (es) Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
AR038326A1 (es) Antibacterianos feniloxazolidinonas sustituidos con heterociclicos biciclicos y composiciones relacionadas y metodos
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR035548A1 (es) Compuestos organicos
AR036111A1 (es) Compuesto de n-[alfa-aminoalcanoil]-3-fluorpirrolidina; composicion farmaceutica formulada con dicho compuesto; su uso en la preparacion de dicha composicion y metodo para el tratamiento de la diabetes tipo 2 utilizando dicho compuesto
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
CO4970728A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
AR036041A1 (es) Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR044629A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
CO5690598A2 (es) 6-[(sustituido)fenil]triazolopirimidinas como agentes anticancer
AR062405A1 (es) Derivados de isoindol

Legal Events

Date Code Title Description
FC Application refused